CancerDrs

Breast Cancer clinical trials in Mississippi

11 actively recruiting breast cancer trials at 9 sites across Mississippi.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
  • Baptist Cancer Center-Grenada — Grenada, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Desoto — Southhaven, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
  • Baptist Cancer Center-Grenada — Grenada, Mississippi
  • University of Mississippi Medical Center — Jackson, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
  • Baptist Cancer Center-Grenada — Grenada, Mississippi
  • University of Mississippi Medical Center — Jackson, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Mississippi:
  • Gulfport Memorial Hospital — Gulfport, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
  • Baptist Cancer Center-Grenada — Grenada, Mississippi
  • University of Mississippi Medical Center — Jackson, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …

Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
  • Baptist Cancer Center-Grenada — Grenada, Mississippi
  • Mississippi Baptist Medical Center — Jackson, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
  • Baptist Cancer Center-Grenada — Grenada, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
  • Baptist Memorial Hospital and Cancer Center-Desoto — Southhaven, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…

Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Mississippi:
  • Baptist Clinical Research Institution — Oxford, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…

Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in Mississippi:
  • North Mississippi Hematology and Oncology Associates — Tupelo, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Mississippi:
  • Clinical Trial Site — Jackson, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…

Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Mississippi:
  • University of Mississippi Medical Center — Jackson, Mississippi
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19